CO2022010592A2 - Métodos de tratamiento de la esplenomegalia - Google Patents

Métodos de tratamiento de la esplenomegalia

Info

Publication number
CO2022010592A2
CO2022010592A2 CONC2022/0010592A CO2022010592A CO2022010592A2 CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2 CO 2022010592 A CO2022010592 A CO 2022010592A CO 2022010592 A2 CO2022010592 A2 CO 2022010592A2
Authority
CO
Colombia
Prior art keywords
splenomegaly
methods
treatment
therapeutic methods
treating
Prior art date
Application number
CONC2022/0010592A
Other languages
English (en)
Spanish (es)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CO2022010592A2 publication Critical patent/CO2022010592A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CONC2022/0010592A 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia CO2022010592A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CO2022010592A2 true CO2022010592A2 (es) 2022-10-31

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010592A CO2022010592A2 (es) 2020-01-08 2022-07-28 Métodos de tratamiento de la esplenomegalia

Country Status (15)

Country Link
EP (2) EP3980069A4 (https=)
JP (2) JP7771064B2 (https=)
KR (1) KR20220130151A (https=)
CN (1) CN114423457A (https=)
AU (1) AU2021205484A1 (https=)
BR (1) BR112022013646A2 (https=)
CA (1) CA3164063A1 (https=)
CO (1) CO2022010592A2 (https=)
CR (1) CR20220374A (https=)
IL (1) IL294582A (https=)
JO (1) JOP20220168A1 (https=)
MA (3) MA63848B1 (https=)
MX (1) MX2022008490A (https=)
TN (1) TN2022000185A1 (https=)
WO (1) WO2021142257A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
IL309238A (en) * 2021-06-16 2024-02-01 Telios Pharma Inc Treatment of symptoms associated with myeloproliferative tumors
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
CN119677518A (zh) * 2022-08-25 2025-03-21 百济神州(苏州)生物科技有限公司 包含(s)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺和草酸的固体形式、其组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN112313214A (zh) * 2018-06-19 2021-02-02 默克专利有限公司 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY

Also Published As

Publication number Publication date
EP4000624A1 (en) 2022-05-25
AU2021205484A1 (en) 2022-08-18
JP2026027353A (ja) 2026-02-18
MA57226B1 (fr) 2023-06-28
CR20220374A (es) 2023-01-25
MA57226A1 (fr) 2023-02-28
EP3980069A1 (en) 2022-04-13
JOP20220168A1 (ar) 2023-01-30
MX2022008490A (es) 2022-10-13
MA63848A1 (fr) 2024-04-30
JP2023509968A (ja) 2023-03-10
MA63848B1 (fr) 2024-10-31
TN2022000185A1 (en) 2024-04-01
MA69153A1 (fr) 2025-07-31
KR20220130151A (ko) 2022-09-26
CA3164063A1 (en) 2021-07-15
WO2021142257A1 (en) 2021-07-15
JP7771064B2 (ja) 2025-11-17
BR112022013646A2 (pt) 2022-10-04
IL294582A (en) 2022-09-01
EP3980069A4 (en) 2022-08-17
CN114423457A (zh) 2022-04-29

Similar Documents

Publication Publication Date Title
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
CO2020014599A2 (es) Métodos para tratar cáncer
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
MX393452B (es) Tratamiento de los trastornos depresivos.
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
EP4438048A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO T LYMPHOCYTES
MX2025008834A (es) Proteinas de fusion anti-pd-1/il-2, composiciones farmaceuticas y aplicaciones terapeuticas
JOP20240197A1 (ar) أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
BR112019022676A2 (pt) método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar